For seed innovators, winning investment means showing who will buy, what development will cost, and when the science can deliver a return.
For seed innovators, attracting capital takes a credible path to market, realistic timelines, and a clear understanding of the problem their technology solves.
A promising discovery can earn scientific validation and still leave an investor with an unanswered question: How does this become a business?
For seed companies and technology developers, the answer takes more than a compelling account of what new genetics or gene editing could accomplish. It requires a customer, a realistic development schedule, and a financial case that holds up beyond the presentation.
Paola de Almeida sees a recurring disconnect between the sophistication of agricultural science and the commercial thinking needed to put it to work. Developers can explain their technology in extraordinary detail, yet struggle to explain where it fits, why someone would buy it, or when an investor could expect a return.
“You can’t create something that’s relevant, particularly commercially relevant, unless you understand the system you’re trying to affect,” she said.
De Almeida, CEO and co-founder of strategy and investment advisory firm Natural Systems Capital, addressed that gap during the first installment of The Future of American Agriculture, a webinar series from the Council for Agricultural Science and Technology (CAST). The Sept. 30 session, “Investment and Competitiveness: Aligning Capital with Agricultural Priorities,” featured a presentation and discussion with CAST CEO Chris Boomsma.
De Almeida’s assessment covered agricultural investment broadly, but she explicitly included gene editing, plant genetics, and biological interventions among the technologies that need a clearer connection between scientific potential, commercial readiness, and financing.
For the U.S. seed industry, the discussion offers a useful lens on commercialization: how to build a business case that is as credible as the science behind it.
Start With the Problem
De Almeida described a familiar trap in technology development: becoming so invested in a solution that the problem it is supposed to address receives too little scrutiny.
Her advice: “Be in love with the problem, and then pressure test your solution.”
That means asking difficult questions early. Who is the customer? Why would that customer change what they already do? What does the technology improve? How large is the market? What will it cost to reach it?
De Almeida recalled using the “five whys” framework during her work in corporate innovation to interrogate proposed offerings. Repeatedly questioning why a product should be developed and why someone would want it helped filter ideas before they advanced through the pipeline.
She argued that some technologies emerging from academia lack the commercial expertise needed to answer those questions, including the ability to build a credible profit-and-loss statement or assess the time required to reach the market.
“Some of the regular practices of innovation practitioners, from a commercialization standpoint, are simply not there because they just don’t understand the market,” she said.
For seed businesses, that puts commercial planning alongside product development from the outset. Performance evidence needs to connect to a specific customer need and a plausible route to revenue. An impressive technology doesn’t explain those things on its own.
Match the Money to the Milestone
Even a well-defined opportunity can run into trouble when the financing doesn’t fit the development schedule.
“Not all capital is created equal,” de Almeida said.
Equity, loans, and insurance serve different functions. The right financial mechanism depends on the stage of development, the scale of the investment, and the risks involved.
De Almeida described a mismatch between investors seeking returns or exits within five to 10 years and agricultural investments that may require a longer runway. She also cautioned that some technologies aren’t mature enough to meet the expectations attached to the capital they seek.
That mismatch can create pressure to promise more than a technology can deliver.
She pointed to alternative proteins as a cautionary example. Early enthusiasm attracted capital and inflated valuations, she said, before some technologies could produce the results promised within the expected time frame. Losses then damaged investor appetite for further funding.
Her point was that a technology can have a useful role and still be financed against the wrong expectations. She extended that warning to biological interventions, gene editing and plant genetics, calling for honesty about their maturity, their place in agricultural systems, and the infrastructure needed to support them.
For seed innovators, that means making the remaining development work explicit and seeking capital suited to it. Investors need to understand what their money will accomplish, how long that work will take, and how the business eventually expects to generate a return.
“At some point, they might put that capital into the system, but that capital needs to come back,” she said.
Build Adoption into the Business Case
During the audience Q&A, a question about growers’ ability to afford new technology brought the discussion back to the customer.
De Almeida emphasized the need to account for the full cost of a transition, including changes to existing practices or processes. A technology may perform well but fit poorly with the way an operation currently works.
“What else needs to change in their practices that would create extra cost that’s not being considered right now?” she asked.
For seed companies, that’s a commercialization question. Where a product requires additional management, services, or other operational changes, those costs affect the customer’s decision to buy — and the developer’s assumptions about market uptake. Understanding them early makes the sales proposition and the investment case more credible.
Make the Evidence Usable
De Almeida also challenged the idea that more data will automatically unlock investment. Markets already have substantial information, she said. The difficulty is turning it into insights that help investors evaluate opportunities and risks.
For seed businesses, that suggests a practical task: connect technical results to the commercial problem being addressed. Explain what improves, under which conditions, for which customers, and at what cost. Be equally clear about what remains uncertain.
Looking toward 2040, de Almeida expressed confidence in American scientific institutions and the quality of the solutions they have developed. The challenge, she argued, is translating that knowledge into practical deployment at scale.
For seed innovators, that work includes the business model, the financing, and the conditions needed for customers to adopt a product. Each deserves attention before expectations — and valuations — run ahead of the technology.
The next investor conversation needs to explain how the breakthrough becomes a business.
